2024
Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation
May C, Noble P, Herzog E, Meffre E, Hansen J. Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation. Biochemical And Biophysical Research Communications 2024, 720: 150123. PMID: 38759301, DOI: 10.1016/j.bbrc.2024.150123.Peer-Reviewed Original ResearchDiffuse cutaneous systemic sclerosisCutaneous systemic sclerosisAnti-topoisomerase 1Systemic lupus erythematosusDiscovery of autoantibodiesMechanisms of autoimmunityInhibit DNA repairScleroderma autoantibodiesScleroderma subtypeSystemic sclerosisLupus erythematosusAutoantibodiesCancer therapyPathophysiologyReagent resourcesCellular dysfunctionAntibodiesCell nucleiDNA repair
2021
Chapter 48 Malignancies in systemic lupus erythematosus
Ladouceur A, Tissera H, Clarke A, Ramsey-Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 48 Malignancies in systemic lupus erythematosus. 2021, 461-467. DOI: 10.1016/b978-0-12-814551-7.00048-9.ChaptersSystemic lupus erythematosusSLE patientsLupus erythematosusGeneral populationOverall cancer incidence ratesHormone-sensitive cancersCancer incidence ratesRisk of breastDrug exposureIncidence rateProstate cancerHormonal changesHigh riskCancer profilePatientsCancerGenetic factorsErythematosusRiskPotential reasonsLymphomaMalignancyPathophysiologyPopulationBreast
2018
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre Y, Clarke AE. Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. The Journal Of Rheumatology 2018, 45: 393-396. PMID: 29335347, PMCID: PMC5834350, DOI: 10.3899/jrheum.170652.Peer-Reviewed Original ResearchConceptsLung cancer risk factorsSystemic lupus erythematosusCancer risk factorsLung cancer casesLung cancer riskLung cancerRisk factorsSLE cohortDisease activityLupus erythematosusDrug exposureCancer casesCancer riskMcGill University Health CentreCumulative disease activityIncident lung cancerUniversity Health CentreCancer risk studiesInstitutional review boardHigher SLEDAIMedication exposureSLE controlsAdjusted effectHealth centersAdjusted model
2016
Breast cancer in systemic lupus
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin P, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016, 26: 311-315. PMID: 27687028, PMCID: PMC5250552, DOI: 10.1177/0961203316664595.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusBreast cancer riskAnti-dsDNA positivityBreast cancer casesBreast cancerCancer riskDisease activitySLE patientsHazard ratioCancer casesSLE samplesBreast cancer hazard ratioCancer hazard ratioCumulative disease activityFemale SLE patientsCase-cohort analysisCancer-free controlsCohort entrySLE durationClinical characteristicsSystemic lupusClinical factorsLupus erythematosusDrug exposureFamily historyChapter 46 Malignancies in Systemic Lupus Erythematosus
Tissera H, Clarke A, Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 46 Malignancies in Systemic Lupus Erythematosus. 2016, 411-415. DOI: 10.1016/b978-0-12-801917-7.00046-2.ChaptersSystemic lupus erythematosusSLE patientsGeneral populationLupus erythematosusOverall cancer incidence ratesHormone-sensitive cancersCancer incidence ratesRisk of breastDrug exposureIncidence rateProstate cancerHormonal changesHigh riskCancer profilePatientsCancerGenetic factorsErythematosusRiskPopulationPotential reasonsLymphomaMalignancyPathophysiologyBreast
2014
A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells
Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Scientific Reports 2014, 4: 5958. PMID: 25091037, PMCID: PMC5380011, DOI: 10.1038/srep05958.Peer-Reviewed Original ResearchConceptsLupus autoantibodiesTherapeutic agentsCancer cellsSystemic lupus erythematosusBRCA2-deficient cellsLupus erythematosusBRCA2-deficient cancer cellsDLD1 colon cancer cellsColon cancer cellsSuch antibodiesLower riskAutoantibodiesSpecific cancersAntibodiesMalignancyDifferential effectsToxic effectsPotential utilityCellsAgentsFurther supportDNA-damaging agentsErythematosusTherapyCancerSystemic Lupus Erythematosus and Malignancies A Review Article
Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, Gordon C, Hansen JE, Bernatsky S. Systemic Lupus Erythematosus and Malignancies A Review Article. Rheumatic Disease Clinics Of North America 2014, 40: 497-506. PMID: 25034158, DOI: 10.1016/j.rdc.2014.04.005.Commentaries, Editorials and LettersConceptsSystemic lupus erythematosus populationRisk of lymphomaSystemic lupus erythematosusCancer risk profileHormone-sensitive cancersLung cancer riskRisk of cancerImmunosuppressive medicationsCervical dysplasiaLupus erythematosusDecreased riskSimilar pathophysiologyCancer riskHepatic carcinomaSLERisk profileRecent dataRiskHigh rateCancerReview articleErythematosusMedicationsLupusCarcinoma
2013
Breast Cancer in Systemic Lupus Erythematosus
Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S. Breast Cancer in Systemic Lupus Erythematosus. Oncology 2013, 85: 117-121. PMID: 23887245, PMCID: PMC3934367, DOI: 10.1159/000353138.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusSLE durationHistological typeBreast cancerDuctal carcinomaSLE cohortLupus erythematosusMultivariate logistic regression analysisDuctal histological typeIndependent risk factorCommon histological typeBreast cancer riskLogistic regression analysisRegression analysisLobular adenocarcinomaIndependent predictorsMixed histologyCancer RegistryRisk factorsHistological statusCancer riskCarcinomaHistology informationCancerCancer dates
2012
Targeting Cancer with a Lupus Autoantibody
Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine 2012, 4: 157ra142. PMID: 23100628, PMCID: PMC3713477, DOI: 10.1126/scitranslmed.3004385.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAnti-DNA antibodiesLupus autoantibodiesProstate cancerCancer therapyLupus anti-DNA antibodiesHuman tumor xenograftsDNA-damaging therapiesCultured tumor cellsSLE patientsLupus erythematosusSLE pathophysiologyAutoimmune diseasesDose doxorubicinTumor xenograftsAutoantibodiesHuman cancer cellsTherapyTherapeutic agentsTumor cellsCancerCancer cellsLupusMalignancyPrecise role